Targeting Ribosome Biogenesis to Combat Tamoxifen Resistance in ER+ve Breast Cancer

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Breast cancer is a heterogeneous disease, with estrogen receptor-positive (ER+) subtypes comprising about 70% of cases.
• Tamoxifen is a standard adjuvant therapy for ER+ breast cancer, but acquired resistance develops in approximately half of patients.
• Overexpression of the c-MYC oncogene is implicated in ER+ breast cancer development and tamoxifen resistance.

Purpose of the Study:

• To investigate the role of c-MYC-mediated ribosome biogenesis in tamoxifen resistance in ER+ breast cancer.
• To explore the potential of ribosome biogenesis inhibitors to overcome tamoxifen resistance.

Main Methods:

• The study focuses on the molecular mechanisms linking c-MYC overexpression to enhanced ribosome biogenesis and protein translation via eIF4E.
• It discusses the potential application of known ribosome biogenesis inhibitors (CX-5461, CX-3543, haemanthamine) in reversing tamoxifen resistance.
• The need for predictive markers for identifying patients who would benefit from these inhibitors is highlighted.

Main Results:

• c-MYC overexpression drives ER+ breast cancer and tamoxifen resistance, partly by enhancing ribosome biogenesis.
• Increased ribosome production supports high cell proliferation and resistance to apoptosis.
• c-MYC induces eIF4E, promoting translation of oncogenic factors that contribute to tamoxifen resistance.

Conclusions:

• Suppressing ribosome biogenesis is a potential strategy to reduce breast cancer aggressiveness and reverse tamoxifen resistance.
• Ribosome biogenesis inhibitors like CX-5461, CX-3543, and haemanthamine may be effective if c-MYC-driven ribosome biogenesis is key to resistance.
• Future clinical application requires the identification of predictive biomarkers for patient selection.